Pharmacogenetics of metformin response in Iranian patients with polycystic ovary syndrome (PCOS) in Peroxisome Proliferator activated receptor gamma (PPAR y) gene

Background: Polycystic ovary syndrome (PCOS) is now characterized as an important metabolic, reproductive disturbance and ovulatory dysfunction insulin resistance.In the peroxisome in proliferator-activated receptor gamma (PPAR y) gene, a polymorphism Pro 12 Ala , has been shown to change amino acid residue of proline with alanine and affect PPAR y function. PPAR y is a transcription factor and is an important regulator of adipogenesis that Pro12Ala polymorphism alleviates its transcriptional activity. Metformin improves insulin ovulation in PCOS patients. The aim of this study was to investigate the relationship between Pro12Ala polymorphism and metformin consumption in patients with PCOS.Methods: A total of 100 reproductive-aged women included in this case study were diagnosed as a PCOS based on Rotterdam criteria and 100 healthy women with no evidence of PCOS were recruited as controls. The plasma levels of follicle-stimulating hormone (FSH), and luteinizing hormone (LH) was evaluated before and 45 days after metformin consumption in patients. The case and control group was genotyped using the technique PCR-RFLP for Pro12Ala polymorphism.Result: After genotyping, there was not any significant difference in patient and control groups. In patient, LH, FSH, and testosterone levels was significantly different but there was no correlation between genotype and response to metformin (p-value=0.59).Conclusion: The study was done to obtain ovulatory response to treatment of metformin in a prospective randomized trial. The interaction with the effects of changes in genetic or modifiable factors requires further study.

Keywords:

FSH , Genotyping , Metformin , PCR-RFLP , Polymorphism , PPAR y gene , Pro12Ala , LH , PCOS